Who
George Elston
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, EyePoint; Chief Financial Officer, Juniper Pharmaceuticals; Director, Celldex Therapeutics.
In numbers
- Trades disclosed
- 109
- Buys
- 5
- Sells
- 0
- Bought
- $40K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 25 Sep 2008
- Last trade
- 20 Aug 2026
- Last filed
- 24 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 24 Aug 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code J | —5,000 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code J | —5,000 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code G | —64,953 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code G | —64,953 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code J | —5,000 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code J | —5,000 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code G | —64,953 at $0.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code G | —64,953 at $0.00 | filing |
| 25 May 2026filed 27 May 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 25 May 2026filed 27 May 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code F | $47K3,627 at $12.93 | filing |
| 25 May 2026filed 27 May 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 25 May 2026filed 27 May 2026 | EYPT EyePointoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 25 May 2026filed 27 May 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 25 May 2026filed 27 May 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code F | $47K3,627 at $12.93 | filing |
| 2 Mar 2026filed 6 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code G | —5,000 at $0.00 | filing |
| 2 Mar 2026filed 6 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code G | —5,000 at $0.00 | filing |
| 2 Mar 2026filed 6 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code G | —5,000 at $0.00 | filing |
| 2 Mar 2026filed 6 Mar 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code G | —5,000 at $0.00 | filing |
| 6 Jan 2026filed 7 Jan 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code M | —15,285 at $0.00 | filing |
| 6 Jan 2026filed 7 Jan 2026 | EYPT EyePointBiotechnology | SEC FORM 4 Code F | $76K4,487 at $16.86 | filing |
News
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Jefferies Financial Group to "Hold"EYPT · tickerreport.com · 19 Oct 2026Critical Review: Eyepoint Pharmaceuticals (NASDAQ:EYPT) and GSK (NYSE:GSK)EYPT · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name George Elston; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.